Parenteral formulations of elacytarabine derivatives

A pharmaceutical composition, comprising a cytarabine derivative of formula I:

• wherein R1 and R3 are hydrogen and R2 is a C18- or C20-saturated or monounsaturated acyl group, or a pharmaceutically acceptable salt thereof as an active ingredient;
• wherein the active ingredient is dissolved or dispersed in a formulation comprising:
• a solubilizer comprising one or more phospholipids,
• a co-solubilizer comprising a surfactant, and
• an isotonicity agent selected from the group consisting of glycerol, propylene glycol, sugars, amino acids, proteins, salts and combinations thereof,
• wherein the formulation has a particle size between 5 nm and 45 nm.